Scilex Holding Company
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$5.77
FAIR PRICE
$10.05
MARGIN
$4.28
P/E Ratio
N/A
Div. Yield
N/A
ROE
181.1%
Exceptional
Market Cap
$58M
Small-cap
FPI RATING
Consistent growth trajectory and attractive valuation, but volatile earnings pattern.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$8.04
Fair price × 0.80
DISTANCE
39.3%
Price to entry level
At the current price of $5.77, SCLX trades 39.3% below the conservative entry level of $8.04. The stock is currently priced below the 20% margin of safety threshold, indicating a potential value opportunity based on the model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
COMING SOON
Get notified when SCLX's fair price changes
Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.
iOS and Android · Free tier available
KEY FACTS
CEO
Henry H. Ji
COUNTRY
US
HEADQUARTERS
Palo Alto
SECTOR
Healthcare
EXCHANGE
NASDAQ
METHODOLOGY
How we calculate SCLX's fair price
Scilex Holding Company's fair price of $10.05 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $5.77, SCLX trades 74.2% below its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting SCLX's risk profile.
RELATIVE · 30%
Comparing SCLX's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for SCLX, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate SCLX's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for SCLX.
Explore on BuliosFAQ
What is the fair price of SCLX?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Scilex Holding Company is $10.05. At the current market price of $5.77, SCLX trades 74.2% below its calculated fair value.
Is SCLX overvalued or undervalued?+
Scilex Holding Company is currently undervalued based on our valuation model. The stock trades at $5.77, which is 74.2% below the fair price of $10.05.
What is the margin of safety for SCLX?+
With a 20% margin of safety applied to the fair price of $10.05, the conservative entry level for SCLX is $8.04. At the current market price of $5.77, the stock trades 39.3% below this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is SCLX's fair price updated?+
We update fair price calculations for SCLX daily after market close. The current fair price of $10.05 incorporates the latest market data and sector multiples.
What factors affect SCLX's fair price calculation?+
SCLX's fair price of $10.05 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of 181.1%.
Is SCLX a good buy right now?+
At $5.77, SCLX trades 74.2% below our fair value estimate of $10.05. The stock is currently undervalued. ROE stands at 181.1% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.
Does SCLX pay dividends?+
SCLX does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.